Taking stock of the drug industry, from the lab to the medicine chestApril 11, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Paul Ratje/The Washington Post 6 burning questions about how the FDA will handle conflicting abortion pill decisions STAT spoke with regulatory and legal experts about what comes next for the FDA and drugmakers after conflicting abortion pill rulings. By Sarah Owermohle and Ed Silverman STAT+ | How many? One-third of late-stage trials testing multiple sclerosis drugs were never published The results from more than one-third of late-stage clinical trials for multiple sclerosis drugs were never published in journals. By Ed Silverman Opinion: The mifepristone debacle is just the latest blow in an ongoing assault on the FDA's authority The mifepristone ruling undermines the FDA's prerogative to approve or reject new drug applications, creating massive uncertainty. By Cartier Esham and John Murphy Adobe STAT+ | A biotech upstart takes on cancer by crowdsourcing the immune system's natural killers The Bay Area biotech believes it can harness the diversity of the immune system to treat a range of deadly cancers. By Jonathan Wosen STAT+ | Oracle's Cerner Enviza launches a new effort to use AI to study asthma drug safety Oracle's Cerner Enviza will work with John Snow Labs on AI tools to search patient records for side effects from the asthma drug montelukast. By Brittany Trang More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments